CA2383224A1 - Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer - Google Patents

Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer Download PDF

Info

Publication number
CA2383224A1
CA2383224A1 CA002383224A CA2383224A CA2383224A1 CA 2383224 A1 CA2383224 A1 CA 2383224A1 CA 002383224 A CA002383224 A CA 002383224A CA 2383224 A CA2383224 A CA 2383224A CA 2383224 A1 CA2383224 A1 CA 2383224A1
Authority
CA
Canada
Prior art keywords
extract
methoxyflavone
hydroxy
animal
resveratrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002383224A
Other languages
English (en)
Other versions
CA2383224C (fr
Inventor
Geetha Ghai
Robert T. Rosen
Chi-Tang Ho
Kuang Yu Chen
Nitin Telang
Martin Lipkin
Mou Tuan Huang
Charles Boyd
Katalin Csiszar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383224A1 publication Critical patent/CA2383224A1/fr
Application granted granted Critical
Publication of CA2383224C publication Critical patent/CA2383224C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2383224A 1999-09-21 2000-09-20 Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer Expired - Fee Related CA2383224C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15501899P 1999-09-21 1999-09-21
US60/155,018 1999-09-21
PCT/US2000/025733 WO2001021137A1 (fr) 1999-09-21 2000-09-20 Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer

Publications (2)

Publication Number Publication Date
CA2383224A1 true CA2383224A1 (fr) 2001-03-29
CA2383224C CA2383224C (fr) 2010-12-07

Family

ID=22553801

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2383224A Expired - Fee Related CA2383224C (fr) 1999-09-21 2000-09-20 Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer

Country Status (5)

Country Link
EP (1) EP1214040A4 (fr)
JP (1) JP2003509447A (fr)
AU (1) AU7384900A (fr)
CA (1) CA2383224C (fr)
WO (1) WO2001021137A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016358A1 (en) * 2000-04-19 2002-02-07 Nof Corporation Cosmetic composition
WO2002039956A2 (fr) * 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Extrait de the noir pour prevention de pathologies
US7087790B2 (en) 2003-08-29 2006-08-08 Rutgers, The State University Of New Jersey Benzotropolone derivatives and modulation of inflammatory response
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20070042972A1 (en) * 2005-05-24 2007-02-22 Mckeever Kenneth H Compositions and methods for optimizing exercise recovery
WO2007135569A2 (fr) * 2006-02-09 2007-11-29 Kgk Synergize Inc Procédés de traitement de l'ostéosarcome canin
WO2008035208A2 (fr) * 2006-05-19 2008-03-27 Kgk Synergize Inc Utilisation de flavonoïdes pour inhiber la croissance cellulaire
CN100422168C (zh) * 2006-06-15 2008-10-01 中国科学技术大学 橙皮素衍生物及其制备方法
DE102007037772A1 (de) * 2007-08-10 2009-02-12 Csabai, Zsolt, Dr. Ph. Antioxidantenkomplex auf Grape Vital Basis (Citrus- und/oder Traubenkern und/oder Flavonoidbasis)
JP5742050B2 (ja) * 2011-03-01 2015-07-01 国立研究開発法人農業・食品産業技術総合研究機構 Nk細胞活性化剤、及びnk細胞活性化方法
WO2013172682A1 (fr) 2012-05-16 2013-11-21 연세대학교 산학협력단 Utilisation d'un composé de flavone pour la prévention ou le traitement de l'obésité
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
CN108601840A (zh) * 2015-12-07 2018-09-28 国立大学法人京都大学 Pd-1信号抑制剂的并用疗法
CN115772145A (zh) * 2022-11-29 2023-03-10 三峡大学 一种柑橘属果实提取物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824320A4 (fr) * 1995-05-05 2000-06-07 Hauser Inc Acide carnosique de grande purete obtenu a partir d'extraits de romarin et de sauge par precipitation a regulation de ph
JPH09176009A (ja) * 1995-12-27 1997-07-08 Inahata Koryo Kk 新規な抗変異原剤及び抗変異原性作用物質
US5830738A (en) * 1996-06-04 1998-11-03 Clemson University Extraction of pigment from plant material
US6251400B1 (en) * 1997-09-26 2001-06-26 Kgk Synergize Inc Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
JP3571899B2 (ja) * 1997-12-18 2004-09-29 小川香料株式会社 香味劣化抑制剤

Also Published As

Publication number Publication date
WO2001021137A1 (fr) 2001-03-29
EP1214040A1 (fr) 2002-06-19
EP1214040A4 (fr) 2004-06-23
CA2383224C (fr) 2010-12-07
JP2003509447A (ja) 2003-03-11
WO2001021137A8 (fr) 2001-07-26
AU7384900A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
CA2383224A1 (fr) Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer
CA2431196A1 (fr) Extrait de the noir pour prevention de pathologies
WO2001080843A3 (fr) Inhibition d'une proliferation cellulaire anormale avec de la camptothecine et combinaisons contenant ledit compose
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
BG66087B1 (bg) Хинолинонови производни като тирозин киназни инхибитори
PL351280A1 (en) Methods and compositions for treating solid tumors
KR100352030B1 (en) Gum composition for removing nicotine
YU75003A (sh) Nutriciona farmaceutska formulacija koja uključuje polifenole i upotreba u tretmanu kancera
AU4451101A (en) Method and compositions for preventing hormone induced adverse effects
CA2326761A1 (fr) Agents antitumoraux
GEP20043322B (en) C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
CA2418479A1 (fr) Promedicaments de derives de l'acide betulinique pour le traitement du cancer et du vih
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
AU4830097A (en) Use of an extract of Cimicifuga
PL313223A1 (en) Nigella sativa as a therapeutic agent
CA2312936A1 (fr) Compositions et techniques pour perte de poids
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
EP0281070A3 (fr) Composé pharmaceutique pour le traitement du cancer
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
WO2002062952A3 (fr) Mutants pap non cytotoxiques
NZ523606A (en) Pharmaceutical compositions and methods for use
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2000037065A3 (fr) Hormonotherapie du cancer du sein associee a un traitement au tamoxifene et aux dibenzofurannes polychlores alkyles

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140922